Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214);The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine

Oncotarget

Volumn 6, Issue 7, 2015, Pages 4992-5004

  Jung, Deok Beom ^a   Yun, Miyong ^a   Kim, Eun Ok ^a   Kim, Jaekwang ^a   Kim, Bonglee ^a   Jung, Ji Hoon ^a   Wang, Enfeng ^b   Mukhopadhyay, Debabrata ^b   Hammond, Edward ^c   Dredge, Keith ^c   Shridhar, Viji ^d   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

^b Department of Biochemistry and Molecular Biology ^*  (United States)

^c Progen Pharmaceuticals Limited   (Australia)

^d Mayo Clinic College of Medicine   (United States)

Author keywords

Gemcitabine; Heparan sulfate mimetic; Pancreatic cancer; PG545; Wnt catenin

Indexed keywords

BETA CATENIN; CYCLIN D1; GEMCITABINE; GLYCOSIDASE INHIBITOR; MATRILYSIN; PG 545; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT3A PROTEIN; WNT7A PROTEIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOMIMETIC MATERIAL; CTNNB1 PROTEIN, HUMAN; DEOXYCYTIDINE; SAPONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL MOTILITY; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOGENESIS; CARCINOMA, PANCREATIC DUCTAL; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CATENIN; BIOMIMETIC MATERIALS; CARCINOGENESIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; RANDOM ALLOCATION; SAPONINS; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925002888     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.27216     Document Type: Erratum

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57(1):43-66.
2. Ghaneh P, Costello E and Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007; 56(8):1134-1152.
3. Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G and Biasco G. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol Rep. 2010; 23(5):1183-1192.
4. Wang L, Heidt DG, Lee CJ, Yang H, Logsdon CD, Zhang L, Fearon ER, Ljungman M and Simeone DM. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell. 2009; 15(3):207-219.
5. Gui S, Yuan G, Wang L, Zhou L, Xue Y, Yu Y, Zhang J, Zhang M, Yang Y and Wang DW. Wnt3a regulates proliferation, apoptosis and function of pancreatic NIT-1 beta cells via activation of IRS2/PI3K signaling. J Cell Biochem. 2013; 114(7):1488-1497.
6. Zhang Y, Morris JPt, Yan W, Schofield HK, Gurney A, Simeone DM, Millar SE, Hoey T, Hebrok M and Pasca di Magliano M. Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res. 2013; 73(15):4909-4922.
7. Cui J, Jiang W, Wang S, Wang L and Xie K. Role of Wnt/beta-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des. 2012; 18(17):2464-2471.
8. Lee MA, Park JH, Rhyu SY, Oh ST, Kang WK and Kim HN. Wnt3a expression is associated with MMP-9 expression in primary tumor and metastatic site in recurrent or stage IV colorectal cancer. BMC Cancer. 2014; 14:125.
9. Kirikoshi H and Katoh M. Expression of WNT7A in human normal tissues and cancer, and regulation of WNT7A and WNT7B in human cancer. Int J Oncol. 2002; 21(4):895-900.
10. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N and Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. Febs J. 2010; 277(19):3890-3903.
11. Arvatz G, Shafat I, Levy-Adam F, Ilan N and Vlodavsky I. The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev. 2011; 30(2):253-268.
12. Dredge K, Hammond E, Davis K, Li CP, Liu L, Johnstone K, Handley P, Wimmer N, Gonda TJ, Gautam A, Ferro V and Bytheway I. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest New Drugs. 2010; 28(3):276-283.
13. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, Brandt R, Ferro V and Bytheway I. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 2011; 104(4):635-642.
14. Ostapoff KT, Awasthi N, Cenik BK, Hinz S, Dredge K, Schwarz RE and Brekken RA. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol Cancer Ther. 2013; 12(7):1190-1201.
15. Hammond E, Brandt R and Dredge K. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PLoS One. 2012; 7(12):e52175.
16. Clevers H and Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012; 149(6):1192-1205.
17. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U and Emerson CP, Jr. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol. 2003; 162(2):341-351.
18. Capurro MI, Xiang YY, Lobe C and Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005; 65(14):6245-6254.
19. Silvestris N, Gnoni A, Brunetti AE, Vincenti L, Santini D, Tonini G, Merchionne F, Maiello E, Lorusso V, Nardulli P, Azzariti A and Reni M. Target therapies in pancreatic carcinoma. Curr Med Chem. 2014; 21(8):948-965.
20. Valenta T, Hausmann G and Basler K. The many faces and functions of beta-catenin. Embo J. 2012; 31(12):2714-2736.
21. Wang Z, Ma Q, Li P, Sha H, Li X and Xu J. Aberrant expression of CXCR4 and beta-catenin in pancreatic cancer. Anticancer Res. 2013; 33(9):4103-4110.
22. Ridgway LD, Wetzel MD and Marchetti D. Heparanase Modulates Shh and Wnt3a Signaling in Human Medulloblastoma Cells. Exp Ther Med. 2011; 2(2):229-238.
23. Cool SM and Nurcombe V. Heparan sulfate regulation of progenitor cell fate. J Cell Biochem. 2006; 99(4):1040-1051.
24. Iozzo RV and San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest. 2001; 108(3):349-355.
25. Beauvais DM and Rapraeger AC. Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol. 2004; 2:3.
26. Sanderson RD and Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis. 2008; 25(2):149-159.
27. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, Zhao G, Smith S, Galcheva-Gargova Z, Karlgren J, Dussault N, Kwan RY, Moy E, Barnes M, Long A, Honan C, et al. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One. 2011; 6(6):e21106.
28. Razavi R, Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M and Kreuzer KA. Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong antitumor efficacy in vivo. Clin Cancer Res. 2011; 17(2):286-293.
29. Kavitha K, Vidya Priyadarsini R, Anitha P, Ramalingam K, Sakthivel R, Purushothaman G, Singh AK, Karunagaran D and Nagini S. Nimbolide, a neem limonoid abrogates canonical NF-kappaB and Wnt signaling to induce caspase-dependent apoptosis in human hepatocarcinoma (HepG2) cells. Eur J Pharmacol. 2012; 681(1-3):6-14.
30. Park JH, Kwon HY, Sohn EJ, Kim KA, Kim B, Jeong SJ, Song JH, Koo JS and Kim SH. Inhibition of Wnt/beta-catenin signaling mediates ursolic acid-induced apoptosis in PC-3 prostate cancer cells. Pharmacol Rep. 2013; 65(5):1366-1374.
31. Zhang YS, Xie JZ, Zhong JL, Li YY, Wang RQ, Qin YZ, Lou HX, Gao ZH and Qu XJ. Acetyl-11-keto-beta-boswellic acid (AKBA) inhibits human gastric carcinoma growth through modulation of the Wnt/beta-catenin signaling pathway. Biochim Biophys Acta. 2013; 1830(6):3604-3615.
32. Jung JH, Kwon TR, Jeong SJ, Kim EO, Sohn EJ, Yun M and Kim SH. Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells. Evid Based Complement Alternat Med. 2013; 2013:805639.
33. Chou TC and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55.